M(2)HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID

BACKGROUND: Opioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV pre-exposure prophylaxis (PrEP) and HCV treatment regimens have transformative potential to address...

Descripción completa

Detalles Bibliográficos
Autores principales: Martel-Laferrière, Valérie, Feaster, Daniel J., Metsch, Lisa R., Shackman, Bruce R., Loignon, Christine, Nosyk, Bohdan, Tookes, Hansel, Behrends, Czarina N., Arruda, Nelson, Adigun, Oluleye, Goyer, Marie-Eve, Kolber, Michael A., Mary, Jean-Francois, Rodriguez, Allan E., Yanez, Iveth G., Pan, Yue, Khemiri, Rania, Gooden, Lauren, Sako, Aïssata, Bruneau, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034074/
https://www.ncbi.nlm.nih.gov/pubmed/35461260
http://dx.doi.org/10.1186/s13063-022-06085-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034074/
https://www.ncbi.nlm.nih.gov/pubmed/35461260
http://dx.doi.org/10.1186/s13063-022-06085-3

Ejemplares similares